GLP-1 weight regain after stopping: what one person's experience won't tell you

What's this video probably claiming?

The creator is pushing back on a common piece of received wisdom: that GLP-1 receptor agonists like semaglutide are a temporary fix, and that stopping them means the weight comes straight back. Her personal evidence is striking. She says she discontinued the medication, went through an entire pregnancy, and still didn't return to her pre-treatment weight. The implied argument is that the "you'll gain it all back" warning is overblown, possibly fearmongering, and that with the right habits or biology, discontinuation doesn't have to mean full regain. It's a relatable counter-narrative to a very loud talking point, and it's gotten 1.3 million views, which means a lot of people are treating this one data point as validation of their own hopes about long-term outcomes.

What does the science actually show?

The regain data is real, and it's not subtle. The STEP 1 trial extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed participants one year after stopping semaglutide 2.4mg. By week 120, two-thirds of lost weight had returned. Participants regained an average of 11.6 of the 17.3 kg they had lost. A similar pattern appeared with liraglutide in the SCALE Obesity and Prediabetes trial. The mechanism isn't surprising: GLP-1 receptor agonists suppress appetite and slow gastric emptying while you're on them. Stop the drug, and those effects largely reverse. That said, "most people regain" is not the same as "every person regains everything." Individual variation is genuine. Factors like duration of treatment, behavior change during treatment, and underlying metabolic differences all matter. The creator's outcome is possible. It is not typical.

Where does the social media noise diverge from clinical reality?

The problem with this video isn't that it's lying. It's that 1.3 million people are watching someone's individual outcome and potentially updating their beliefs about discontinuation risk. That's a category error. N-of-1 anecdotes can't override controlled trial data, no matter how compelling. What makes this one particularly tricky is pregnancy. Gestational physiology alters fat storage, hormonal signaling, and baseline weight in complex ways that have nothing to do with GLP-1 exposure history. Using a post-pregnancy body as proof that GLP-1 discontinuation doesn't cause regain conflates two completely separate variables. It's also worth noting that GLP-1 medications are generally not recommended during pregnancy, so the timeline she's describing likely involved a treatment gap for medical reasons, not an elective "I stopped and was fine" situation.

What should you actually know?

If you're on a GLP-1 medication or considering one, here's the honest framing. The regain risk after stopping is clinically documented and statistically significant. Most people in trials did regain substantial weight within a year of discontinuation. Some people don't, and the reasons why are not fully understood. Ongoing research is looking at whether behavioral interventions during treatment can improve long-term outcomes after stopping (Kaufman et al., 2023, Obesity). Pregnancy adds a confounding variable that makes the creator's personal story essentially uninterpretable as evidence either way. The clinical consensus, including guidance from the Obesity Society, treats GLP-1 medications as long-term or indefinite therapy for most patients, not a course you complete and move on from. Individual outcomes vary. Betting your treatment plan on a viral TikTok is not a strategy.